Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Perspective · 5 Aug 2022 Conference abstract Cancer pharmacogenomics: Discovery science and translational science
biologically any signals identified during our clinical pharmacogenomic GWA studies. We have performed a GWAS using DNA samples from the largest breast cancer prevention trials, the NSABP
Editorial · 17 Aug 2021 Cancer Pharmacogenomics
Pharmacogenomics is the study of how genes affect a person's response
Conference abstract · 31 Aug 2020 Breast Cancer Pharmacogenomics of Aromatase Inhibitors
breast cancer diseases, 70-80% patients have ER+ or hormonal receptor positive breast cancer which makes it the most common subtype. Hormonal therapies including SERMs (selective estrogen receptor modulators…
Conference abstract · 5 Aug 2013 Cancer pharmacogenomic testing, clinician adoption and patient benefit
Background: Cancer pharmacogenomics (caPGx) evaluates the genomic profiles of individuals and their tumors to predict response to treatment, including the potential to select which treatment or dose may be more…
Editorial · 22 Dec 2021 A Brief note on Cancer Pharmacogenomics
Conference abstract · 15 Jun 2017 Tamoxifen pharmacogenomics of breast cancer: the controversy and way forward
million patients dying from the disease each year. The large majority (75%) of breast cancers express the estrogen receptor (ER) making them amenable to targeted endocrine therapy. Standard of care ... clarification of…
Commentary · 4 Aug 2023 Impact of Bioinformatics and Pharmacogenomics on Personalized Cancer Treatment
Commentary · 1 Jun 2023 Exploring the Different Types of Cancer Treatments in Pharmacogenomics
Conference abstract · 15 Aug 2011 Pharmacogenomics predictions for breast cancer treatments? efficacy and toxicity
active form, endoxifen. Therefore, prediction of efficacy and toxicity in breast cancer chemotherapy depends on pharmacogenomics. PHARMAchip� is a DNAchip developed by Progenika Biopharma, SA (Bilbao, Spain) that…
Mini review · 28 Nov 2022 Pharmacogenomics in cancer treatment
Cancer pharmacogenomics has made several significant contributions to current cancer treatment, altering the treatment decision-making paradigm. Both somatic and germline mutations are used to better understand the…
Review article · 2012 Clinical Trials in Cancer and Pharmacogenomics: A Critical Evaluation
blockers or inhibitors with a view to developing successful clinical trials employing personalized cancer therapies. Rational, pharmacogenomic strategies in cancer trials should be adopted that include specific…
Conference abstract Pharmacogenomics of cancer therapeutics: Molecular structure, drug development, and inter-patient variability
C ancer biomarkers are expressed as a result of the development and
Editorial · 30 Oct 2024 Pharmacogenomics in Cancer Treatment Tailoring Therapy for Better Outcomes
improving efficacy and reducing adverse effects. This article reviews the current state of pharmacogenomics in cancer therapy, examining its role in personalized medicine, the challenges in implementation, and the…
Conference abstract Pharmacogenomics of breast cancer endocrine therapy
Breast cancer is the number one invasive cancer of women. Endocrine therapy
Review article · 3 May 2019 Pharmacogenomics and Pharmacogenetics (PGx) - A Connexion to Personalized Cancer Therapy
generally non-particular and has limited remedial index, there is an incredible probability for pharmacogenomics to enhance treatment by either diminishing the various types of toxicity or escalating the efficacy…
Conference abstract · 1 Dec 2018 Pharmacogenomics merges with immunotherapy as world leader in cancer therapy
personalization of breast cancer therapy has relevance in the management of breast cancer. The treatment of malignancy has seen significant advances which have come about because of the ongoing upheaval…
Commentary · 5 Oct 2023 Exploring the Impact of Pharmacogenomics on Gastric Cancer Chemotherapy
Conference abstract Pharmacogenomics predictions for breast cancer treatments? effi cacy and toxicity
form, endoxifen. Th erefore, prediction of effi cacy and toxicity in breast cancer chemotherapy depends on pharmacogenomics. PHARMAchip ? is a DNAchip developed by Progenika Biopharma, SA (Bilbao, Spain) that consists…
Short communication · 19 Apr 2021 Pharmacology and Toxicology 2019: Pathogenic mosaic germline mutational landscape in breast cancer patients and pharmacogenomics - Ryong Nam Kim - Seoul National University
breast cancer patients by carrying out targeted next-generational sequencing of 62 cancer-associated genes. We discovered 112 pathogenic, 37 likely pathogenic and 252 VUS mosaic germline mutations with variant…
Conference abstract · Jan 2021 Pathogenic mosaic germline mutational landscape in breast cancer patients and pharmacogenomics
held at Zurich, Switzerland Pathogenic mosaic germline mutational landscape in breast cancer patients and pharmacogenomics Ryong Nam Kim Seoul National University, Korea cycle, RTK-RAS and PI3K pathways. By using…
Article · 2008 Pharmacogenomics and Pancreatic Cancer Treatment. Optimizing Current Therapy and Individualizing Future Therapy
that pancreatic cancer is a genetic disease which is associated with various forms of cancer associated genetic alterations. Identification and understanding of these carcinogenic gene alterations is the base upon…
Conference abstract · 24 Nov 2020 Pathogenic mosaic germline mutational landscape in breast cancer patients and pharmacogenomics
breast cancer patients by carrying out targeted next-generational sequencing of 62 cancer-associated genes. We discovered 112 pathogenic, 37 likely pathogenic and 252 VUS mosaic germline mutations with variant…
Conference abstract · 21 Sep 2018 Role of Pharmacogenomics in identifying cancer survivors at risk for adverse, persistent toxicities
this presentation is to review current understanding of genetic susceptibility to adverse outcomes among cancer survivors following chemotherapy with a particular focus on genome-wide association studies (GWAS ... rise…
Editorial · 3 Jun 2019 Human Genetics 2018:Role of Pharmacogenomics in identifying cancer survivors at risk for adverse, persistent toxicities_M Eileen Dolan_The University of Chicago,USA
this presentation is to review current understanding of genetic condition to adverse outcomes among cancer survivors following therapy with a specific concentrate on genome-wide association studies (GWAS ... rise within…

